組織工程皮膚治療糖尿病足潰瘍的Meta分析_《中國循證醫學雜志》

作者：

滕永軍 ^1,2 , 王金文 ¹ , 王燕炯 ³ , 楊克虎 ² , 嚴祥 ¹ , 田金徽 ² , 馬彬 ² , 王建民 ¹ ,  李幼平 ^2,4

1. 蘭州大學第一醫院（蘭州 730000）2. 蘭州大學循證醫學中心（蘭州 730000）3. 武警甘肅總隊醫院（蘭州 730000）4. 中國循證醫學中心（成都 610041）;

關鍵詞：

糖尿病足潰瘍組織工程皮膚 Meta 分析

DOI：

10.7507/1672-2531.20090106

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　系統評價組織工程皮膚（tissue-engineered skin，TES）治療糖尿病足潰瘍（diabetic foot ulcer，DFU）的效果。
方法　計算機檢索Cochrane 圖書館、PubMed、EMbase、CBM、CNKI、VIP，手工檢索有關引用文獻，收集以TES 為干預措施治療DFU 的隨機對照試驗（RCT），按Cochrane 系統評價方法，評價納入研究的方法學質量并提取有效數據進行Meta 分析。
結果　共納入7 個RCT，包括880 例DFU 患者。Meta 分析結果顯示：在試驗的12 周中，與保守治療（conventional treatment，CT）相比，TES 明顯促進了DFU 愈合［OR=1.88，95%CI（1.41，2.51）］；在不良反應方面，TES 能降低DFU 的感染機會［RR= – 0.04，95%CI（–0.06，–0.01）］。有2 項試驗對DFU復發進行了分析，提示兩組無明顯差異。
結論　與保守治療相比，TES 能顯著促進DFU 愈合，并可降低DFU 潰瘍面與并發周圍組織感染的機會。

引用本文： 滕永軍,王金文,王燕炯,楊克虎,嚴祥,田金徽,馬彬,王建民,李幼平. 組織工程皮膚治療糖尿病足潰瘍的Meta分析. 中國循證醫學雜志, 2009, 09(5): 584-592. doi: 10.7507/1672-2531.20090106 復制

1.	neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care, 1995, 18(1): 64-69.
2.	noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care, 2003, 26(10): 2853-2859.
3.	Thanh L, Dinh AV. Treatment of diabetic ulcers. Dermatologic Therapy, 2006, 19: 348-355.
4.	Edward JB, Jessie HA, Karin MN, et al. Prediction of Diabetic Foot Ulcer Occurrence Using Commonly Available Clinical Information. Diabetes Care, 2006, 29: 1202-1207.
5.	Sanders LJ. Diabetes mellitus. Prevention of amputation. J Am Podiatr Med Assoc, 1994, 84(7): 322-328.
6.	Managing foot ulcers in patients with diabetes. Drug and Therapeutics Bulletin, 2002, 40(2): 11-14.
7.	Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders: a clinical practice guideline (2006 revision). Journal of Foot and Ankle Surgery, 2006, 45(5): SUPPL. (S1-S66).
8.	Consensus development conference of diabetic foot wound care. Diabetes Care, 1999, 22: 1354-1360.
9.	Eaglstein WH, Iriondo M, Laszlo K. A composite skin substitute (graftskin) for surgical wounds. A clinical experience. Dermatol Surg, 1995, 21: 839-943.
10.	Advanced Tissue Sciences and Smith & Nephew present Dermagraft data. Ostomy Wound Manage, 1997, 43(4): 77-78, 80.
11.	Martin BR, Sangalang M, Wu S, et al. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. International Wound Journal, 2003, 2(2): 161-165.
12.	Gentzkow GD, Scott DI, Kenneth SH. Use of Dermagraft, a Cultured Human Dermis, to Treat Diabetic Foot Ulcers. Diabetes Care, 1996, 19: 350-354.
13.	Richard JL, Parer RC, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic.
14.	Veves AF, Armstrong V, Sabolinski DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care, 2001, 24(2): 290-295.
15.	Elisabeth HH, David KC, Georgette NS, et al. Obtaining Quality Real-world Treatment Data for Economic Models: Methodology and Results of a Wound Care Medical Abstraction Study. www. valuemedics.com/ispor-dfu.pdf, 2003.
16.	Lazareth I. Local care and medical treatment for ischemic diabetic ulcers. Journal des Maladies Vasculaires, 2002, 27(3): 157-163.
17.	American Diabetes Association: Foot care in patients with diabetes mellitus (Position Statement). Diabetes Care, 1996, 19 (Suppl. 1): S23-S24.
18.	Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
19.	Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Jama, 1995, 273(5): 408-412.
20.	Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med, 2002, 21: 1539-1558.
21.	Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. In: Cochrane Library. 2006.
22.	Petitti DB. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis. New York: Oxford University Press, 2000(94-118).
23.	Caravaggi C, De Giglio R, Pritelli C, et al. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of.
24.	Jason R, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg, 2002, 41(5): 291-299.
25.	Richard AP, Howard E, Jeffrey LJ, et al. A Human Dermal Replacement for the Treatment of Diabetic Foot Ulcers. Wounds, 1997, 1(9): 175-183.
26.	Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care, 2003, 26(6): 1701-1705.
27.	Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center’s experience. Dermatol Surg, 2002, 28(8): 698-703.
28.	Eaglstein WH, Alvarez OM, Auletta M. Acute excisional wounds treated with a tissue-engineered skin (Apligraf). Dermatol Surg, 1999, 25: 195-201.
29.	Greenhalgh DG. Wound healing and diabetes mellitus. Clinics in Plastic Surgery, 2003, 30(1): 37-45.
30.	Brem H, Sheehan P, Boulton AJ. Protocol for treatment of diabetic foot ulcers. American Journal of Surgery, 2004, 187(5): SUPPL. 1 (1S-10S).
31.	Metcalfe AD, Ferguson MW. Harnessing wound healing and regeneration for tissue engineering. Biochemical Society Transactions, 2005, 33(2): 413-417.
32.	Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen, 2006, 14(6): 680-692.
33.	American Diabetes Association: Consensus Development Conference on Diabetic Foot Wound Care (Consensus Development Conference Report). Diabetes Care, 1999, 22: 1354-1360.
34.	Gregory SS, Gary SR, Vincent F, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair and Regeneration, 2003, 11: 1-28.
35.	William JJ, Patricia P, Keith GH. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev, 2004, 20(S1): S78-S89.
36.	Rathur HM, Boulton AJM. The diabetic foot. Clinics in Dermatology, 2007, 25(1): 109-120.
37.	Katz I, Harlan A, Miranda PB, et al. A randomized trial of two irremovable off-loading devies in mangement of plantar neuropathic diabetic foot ulcers. Diabetes Care, 2005, 28: 555-559.
38.	Hartsell H, Brand R, Frantz R, et al. The effects of total contact casting materials on plantar pressures. Foot Ankle International, 2004, 25: 73-78.
39.	Birke JA, Pavich MA, Patout CA, et al. Comparison of forefoot ulcer healing using alternative off-loading methods in patients with diabetes mellitus. Adv Skin Wound Care, 2002, 15: 210-215.
40.	Schaper NC, Prompers LM, Huijberts MSP. Treatment of diabetic foot ulcers. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2007, 7(1): 95-104.
41.	Newton DJ, Khan F, Belch JJF, et al. Blood flow changes in diabetic foot ulcers treated with dermal replacement therapy. Journal of Foot and Ankle Surgery, 2002, 41(4): 233-237.
42.	Lorenzi G, Crippa M, Rossi G, et al. Open and endovascular revascularization combined with regenerative dermal skin graft in the treatment of ischemic ulcers. Italian Journal of Vascular and Endovascular Surgery, 2005, 12(2): 61-64.
43.	Allenet B, Pare?e F, Lebrun T, et al. Cost-effectiveness modeling of Dermagraft? for the treatment of diabetic foot ulcers the French context. Diabetes and Metabolism, 2000, 26(2): 125-132.
44.	Dalla PL, Cogo A, Deanesi W, et al. Using hyaluronic acid derivatives and cultured autologous fibroblasts and keratinocytes in a lower limb wound in a patient with diabetes: a case report. Ostomy Wound Manage, 2002, 48(9): 46-49.
45.	Saap LJ, Donohue K, Falanga V. Clinical classification of bioengineered skin use and its correlation with healing of diabetic and venous ulcers. Dermatologic Surgery, 2004, 30(8): 1095-1100.
46.	Loveland LJ, McClure LP, Page JC, et al. Living skin equivalents. Lower Extremity, 1996, 3(4): 231-236.
47.	Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs, 1997, 21(11): 1203-1210.
48.	Ercem A. Current and investigative uses of Graftskin (Apligraf﹫) in wound care introduction. Wounds, 2000, 12(5): 4A-11A.
49.	Sabolinski ML, Alvarez O, Auletta M, et al. Cultured skin as a ’smart material’ for healing wounds: experience in venous ulcers. Biomaterials, 1996, 17(3): 311-320.
50.	Hu S, Kirsner RS, Falanga V, et al. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study. Wound Repair Regen, 2006, 14(4): 427-433.
51.	Curran MP, Plosker GL. Bilayered bioengineered skin substitute (Apligraf?): A review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. BioDrugs, 2002, 16(6): 439-455.
52.	Redekop WK, McDonnell J, Verboom P, et al. The Cost Effectiveness of Apligraf? Treatment of Diabetic Foot Ulcers. Pharmaco Economics, 2003, 21(16): 1171-1183.

1. neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care, 1995, 18(1): 64-69.
2. noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care, 2003, 26(10): 2853-2859.
3. Thanh L, Dinh AV. Treatment of diabetic ulcers. Dermatologic Therapy, 2006, 19: 348-355.
4. Edward JB, Jessie HA, Karin MN, et al. Prediction of Diabetic Foot Ulcer Occurrence Using Commonly Available Clinical Information. Diabetes Care, 2006, 29: 1202-1207.
5. Sanders LJ. Diabetes mellitus. Prevention of amputation. J Am Podiatr Med Assoc, 1994, 84(7): 322-328.
6. Managing foot ulcers in patients with diabetes. Drug and Therapeutics Bulletin, 2002, 40(2): 11-14.
7. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders: a clinical practice guideline (2006 revision). Journal of Foot and Ankle Surgery, 2006, 45(5): SUPPL. (S1-S66).
8. Consensus development conference of diabetic foot wound care. Diabetes Care, 1999, 22: 1354-1360.
9. Eaglstein WH, Iriondo M, Laszlo K. A composite skin substitute (graftskin) for surgical wounds. A clinical experience. Dermatol Surg, 1995, 21: 839-943.
10. Advanced Tissue Sciences and Smith & Nephew present Dermagraft data. Ostomy Wound Manage, 1997, 43(4): 77-78, 80.
11. Martin BR, Sangalang M, Wu S, et al. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. International Wound Journal, 2003, 2(2): 161-165.
12. Gentzkow GD, Scott DI, Kenneth SH. Use of Dermagraft, a Cultured Human Dermis, to Treat Diabetic Foot Ulcers. Diabetes Care, 1996, 19: 350-354.
13. Richard JL, Parer RC, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic.
14. Veves AF, Armstrong V, Sabolinski DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care, 2001, 24(2): 290-295.
15. Elisabeth HH, David KC, Georgette NS, et al. Obtaining Quality Real-world Treatment Data for Economic Models: Methodology and Results of a Wound Care Medical Abstraction Study. www. valuemedics.com/ispor-dfu.pdf, 2003.
16. Lazareth I. Local care and medical treatment for ischemic diabetic ulcers. Journal des Maladies Vasculaires, 2002, 27(3): 157-163.
17. American Diabetes Association: Foot care in patients with diabetes mellitus (Position Statement). Diabetes Care, 1996, 19 (Suppl. 1): S23-S24.
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
19. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Jama, 1995, 273(5): 408-412.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med, 2002, 21: 1539-1558.
21. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. In: Cochrane Library. 2006.
22. Petitti DB. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis. New York: Oxford University Press, 2000(94-118).
23. Caravaggi C, De Giglio R, Pritelli C, et al. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of.
24. Jason R, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg, 2002, 41(5): 291-299.
25. Richard AP, Howard E, Jeffrey LJ, et al. A Human Dermal Replacement for the Treatment of Diabetic Foot Ulcers. Wounds, 1997, 1(9): 175-183.
26. Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care, 2003, 26(6): 1701-1705.
27. Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center’s experience. Dermatol Surg, 2002, 28(8): 698-703.
28. Eaglstein WH, Alvarez OM, Auletta M. Acute excisional wounds treated with a tissue-engineered skin (Apligraf). Dermatol Surg, 1999, 25: 195-201.
29. Greenhalgh DG. Wound healing and diabetes mellitus. Clinics in Plastic Surgery, 2003, 30(1): 37-45.
30. Brem H, Sheehan P, Boulton AJ. Protocol for treatment of diabetic foot ulcers. American Journal of Surgery, 2004, 187(5): SUPPL. 1 (1S-10S).
31. Metcalfe AD, Ferguson MW. Harnessing wound healing and regeneration for tissue engineering. Biochemical Society Transactions, 2005, 33(2): 413-417.
32. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen, 2006, 14(6): 680-692.
33. American Diabetes Association: Consensus Development Conference on Diabetic Foot Wound Care (Consensus Development Conference Report). Diabetes Care, 1999, 22: 1354-1360.
34. Gregory SS, Gary SR, Vincent F, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair and Regeneration, 2003, 11: 1-28.
35. William JJ, Patricia P, Keith GH. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev, 2004, 20(S1): S78-S89.
36. Rathur HM, Boulton AJM. The diabetic foot. Clinics in Dermatology, 2007, 25(1): 109-120.
37. Katz I, Harlan A, Miranda PB, et al. A randomized trial of two irremovable off-loading devies in mangement of plantar neuropathic diabetic foot ulcers. Diabetes Care, 2005, 28: 555-559.
38. Hartsell H, Brand R, Frantz R, et al. The effects of total contact casting materials on plantar pressures. Foot Ankle International, 2004, 25: 73-78.
39. Birke JA, Pavich MA, Patout CA, et al. Comparison of forefoot ulcer healing using alternative off-loading methods in patients with diabetes mellitus. Adv Skin Wound Care, 2002, 15: 210-215.
40. Schaper NC, Prompers LM, Huijberts MSP. Treatment of diabetic foot ulcers. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2007, 7(1): 95-104.
41. Newton DJ, Khan F, Belch JJF, et al. Blood flow changes in diabetic foot ulcers treated with dermal replacement therapy. Journal of Foot and Ankle Surgery, 2002, 41(4): 233-237.
42. Lorenzi G, Crippa M, Rossi G, et al. Open and endovascular revascularization combined with regenerative dermal skin graft in the treatment of ischemic ulcers. Italian Journal of Vascular and Endovascular Surgery, 2005, 12(2): 61-64.
43. Allenet B, Pare?e F, Lebrun T, et al. Cost-effectiveness modeling of Dermagraft? for the treatment of diabetic foot ulcers the French context. Diabetes and Metabolism, 2000, 26(2): 125-132.
44. Dalla PL, Cogo A, Deanesi W, et al. Using hyaluronic acid derivatives and cultured autologous fibroblasts and keratinocytes in a lower limb wound in a patient with diabetes: a case report. Ostomy Wound Manage, 2002, 48(9): 46-49.
45. Saap LJ, Donohue K, Falanga V. Clinical classification of bioengineered skin use and its correlation with healing of diabetic and venous ulcers. Dermatologic Surgery, 2004, 30(8): 1095-1100.
46. Loveland LJ, McClure LP, Page JC, et al. Living skin equivalents. Lower Extremity, 1996, 3(4): 231-236.
47. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs, 1997, 21(11): 1203-1210.
48. Ercem A. Current and investigative uses of Graftskin (Apligraf﹫) in wound care introduction. Wounds, 2000, 12(5): 4A-11A.
49. Sabolinski ML, Alvarez O, Auletta M, et al. Cultured skin as a ’smart material’ for healing wounds: experience in venous ulcers. Biomaterials, 1996, 17(3): 311-320.
50. Hu S, Kirsner RS, Falanga V, et al. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study. Wound Repair Regen, 2006, 14(4): 427-433.
51. Curran MP, Plosker GL. Bilayered bioengineered skin substitute (Apligraf?): A review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. BioDrugs, 2002, 16(6): 439-455.
52. Redekop WK, McDonnell J, Verboom P, et al. The Cost Effectiveness of Apligraf? Treatment of Diabetic Foot Ulcers. Pharmaco Economics, 2003, 21(16): 1171-1183.

上一篇
噻唑烷二酮類藥物治療代謝綜合征的系統評價
下一篇
幽門螺桿菌感染與腦梗死及其亞型關系的Meta分析

《中國循證醫學雜志》

組織工程皮膚治療糖尿病足潰瘍的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

組織工程皮膚治療糖尿病足潰瘍的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料